Last reviewed · How we verify
NCT05600803
Screening Single-operator Cholangioscopy for Neoplastic Bile Duct Lesions
trial testing Single-operator cholangioscopy in Cholangiocarcinoma in 236 participants. Status unknown.
30 October 2025
Quick facts
| Lead sponsor | Soonchunhyang University Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 236 |
| Start date | 30 October 2022 |
| Primary completion | 30 October 2025 |
| Estimated completion | 30 October 2025 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Single-operator cholangioscopy
Conditions studied
- Cholangiocarcinoma — all drugs for Cholangiocarcinoma →
- Bile Duct Neoplasms — all drugs for Bile Duct Neoplasms →
Sponsor
Soonchunhyang University Hospital
Who can join
Adults 19 to 75, any sex, with Cholangiocarcinoma or Bile Duct Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is the prospective observational study to explore whether the SpyGlass DS II system could be used to screen early-stage neoplastic bile duct lesions in selected patients.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Diagnostic Utility of Digital Single-Operator Cholangioscopy for Risk-Enriched Detection and Surveillance of Intraductal Neoplasms of the Bile Duct: SPY-SCREEN Study (with Videos).
Shin IS, Moon JH, Lee YN, Park JW, et al · · 2026 · PMID 42043470 · DOI 10.1007/s10620-026-09863-0
Verify or expand the search:
- PubMed search for NCT05600803
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cholangiocarcinoma
Currently open trials in the same condition.
- NCT07486713 — Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies · Phase 4 · recruiting
- NCT07291947 — PULSAR Combined With Immunotherapy and Chemotherapy · Phase 1, PHASE2 · recruiting
- NCT07359586 — Laryngopharyngeal Injury After Endotracheal Intubation Under General Anesthesia · recruiting
- NCT07263217 — Mechanistic Study on the Protective and Regenerative Effects of Spirulina in Hepatectomy-Related Liver Injury · NA · recruiting
- NCT07155525 — Tissue Adhesive Glue Modified Cyanoacrylate (Glubran® 2) in Soft Pancreas · Phase 3 · recruiting
Other Soonchunhyang University Hospital trials
Trials by the same sponsor.
- NCT07213596 — Virtual Reality Treatment for Trauma Related to COVID-19 Infection · NA · not yet recruiting
- NCT06950489 — Tegoprazan and Amoxicillin Dual Therapy · recruiting
- NCT06682533 — Tegoprazan- Versus PPI-based H. Pylori Eradication · recruiting
- NCT06684860 — RUT vs. Molecular Testing for H. Pylori · recruiting
- NCT06369896 — Digital Single-operator Cholangioscopy and Intraductal Ultrasound for Nonicteric Biliary Strictures · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05600803 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Soonchunhyang University Hospital
- Last refreshed: 27 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05600803.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing